Commentary
Anumakonda V
Abstract
ICNARC data from UK ICU has demonstrated 125% increase in patients requiring ICU admission for advance ventilator support following a severe Community- Acquired Pneumonia (CAP). They constitute one of critically ill patient’s cohorts in ICU. Cardiovascular (CVS) morbidity and mortality associated with CAP has been well-known for several decades. Macrolides form integral part of antibiotic bundle worldwide in management of severe CAP in the ICU setting. We attempt to suggest strategy to mitigate CVS morbidity and mitigate this risk.